- Home
- LDWY vs ADXN Comparison
LDWY vs ADXN Comparison
Compare LDWY & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- ADXN
- Stock Information
- Founded
- LDWY 1990
- ADXN 2002
- Country
- LDWY United States
- ADXN Switzerland
- Employees
- LDWY N/A
- ADXN N/A
- Industry
- LDWY Advertising
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- ADXN Health Care
- Exchange
- LDWY Nasdaq
- ADXN Nasdaq
- Market Cap
- LDWY 9.2M
- ADXN 8.0M
- IPO Year
- LDWY 1991
- ADXN N/A
- Fundamental
- Price
- LDWY $4.95
- ADXN $10.85
- Analyst Decision
- LDWY
- ADXN Strong Buy
- Analyst Count
- LDWY 0
- ADXN 1
- Target Price
- LDWY N/A
- ADXN $30.00
- AVG Volume (30 Days)
- LDWY 5.7K
- ADXN 61.3K
- Earning Date
- LDWY 08-28-2025
- ADXN 09-01-2025
- Dividend Yield
- LDWY N/A
- ADXN N/A
- EPS Growth
- LDWY N/A
- ADXN N/A
- EPS
- LDWY 1.66
- ADXN 0.10
- Revenue
- LDWY $71,244,000.00
- ADXN $278,508.00
- Revenue This Year
- LDWY N/A
- ADXN $86.57
- Revenue Next Year
- LDWY N/A
- ADXN N/A
- P/E Ratio
- LDWY $3.06
- ADXN $0.84
- Revenue Growth
- LDWY 187.12
- ADXN N/A
- 52 Week Low
- LDWY $3.02
- ADXN $6.51
- 52 Week High
- LDWY $6.19
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- LDWY 41.34
- ADXN 68.95
- Support Level
- LDWY $4.64
- ADXN $8.88
- Resistance Level
- LDWY $5.35
- ADXN $12.05
- Average True Range (ATR)
- LDWY 0.33
- ADXN 0.47
- MACD
- LDWY -0.08
- ADXN 0.28
- Stochastic Oscillator
- LDWY 20.00
- ADXN 72.41
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.